港股医药板块大幅回调，资金逆势加仓，关注港股通创新药ETF易方达（159316）等产品投资机会

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 5.4% this week, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 4.5% [1] - The total value of China's innovative drug License-out transactions grew from $2.562 billion in 2017 to $140.274 billion by 2025, indicating enhanced international competitiveness [1] - Over 70% of innovative drug companies are expected to achieve positive revenue growth by 2025, marking a transition into a commercialization phase for the industry [1] Group 2 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has a cumulative decline of 5.6% over the past month and a 44.5% increase over the past year [5] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index has shown a cumulative increase of 46.2% over the past year, while the CSI Innovative Drug Industry Index has increased by 14.5% [5] - The CSI Biotech Theme Index has a cumulative decline of 24.1% over the past three years, while the CSI Pharmaceutical and Health Index has decreased by 25.3% [5]